In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GSK to get siRNA respiratory therapies from Sirna

Executive Summary

In a multi-year deal, Sirna Therapeutics (treatments based on RNA interference) will provide GlaxoSmithKline with short interfering RNA (siRNA) formulations for the treatment of respiratory diseases such as asthma and COPD.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register